UK Markets open in 1 hr 15 mins

iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members

·4-min read

DGAP-News: iOmx Therapeutics AG / Key word(s): Personnel
iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members
20.07.2022 / 09:30
The issuer is solely responsible for the content of this announcement.

iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members

Martinsried / Munich, Germany, 20 July 2022 - iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of three new members to its Supervisory Board: Matthias Kromayer, Ph.D., Managing Partner at MIG Capital and one of Germany’s most experienced life science venture capitalists; Michael Burgess, M.B.Ch.B., Ph.D., a highly respected pharma R&D and oncology drug development leader; and Rainer Kramer, Ph.D., a highly experienced pharmaceutical and biotechnology dealmaker, were named Supervisory Board members.

The Supervisory Board now consists of six members including: Chairman Gerald H. Moeller, Ph.D., former CEO of the Boehringer Mannheim Group; Vice-chairwoman Henrijette Richter, Ph.D., managing partner at Sofinnova Partners; and Rainer Strohmenger, M.D., managing partner at Wellington Partners.

“We are delighted to welcome Matthias Kromayer, Mike Burgess, and Rainer Kramer to the Supervisory Board,” said Dr. Gerald H. Moeller, Chairman of the Supervisory Board of iOmx Therapeutics. “Their collective experience in the global biopharmaceutical industry will be of great value as we advance our exciting platform and pipeline of novel immune checkpoint programs. Our lead product candidate OMX-0407, a first-in-class, oral SIK3 inhibitor, will enter into clinical development towards the end of this year. The next-generation checkpoint inhibitors we are developing have the potential to breakdown the inherent resistance mechanisms of tumors against immune attack and address the gaps in current cancer immunotherapy treatment options.”

Matthias Kromayer, Ph.D., is Managing Partner at MIG Capital, where he oversees the life sciences side of the business. He has been involved in multiple exits of biotech companies including three IPOs, two on Nasdaq (BioNTech, Immatics). Prior to MIG, Matthias was Managing Partner at a strategic consultancy in the life sciences sector. In addition, he has entrepreneurial experience in building and running several companies within and outside of the life sciences sector.

Michael Burgess, M.B.Ch.B., Ph.D., has over 20 years of drug research and development experience in oncology. He currently serves as Head of Research and Development at SpringWorks Therapeutics and also serves on the boards of Turnstone Biologics and Synlogic Therapeutics. Prior to this, Mike held several senior leadership positions in research, early development and clinical pharmacology at Bristol-Myers Squibb, Roche Pharmaceuticals and Eli Lilly.

Rainer Kramer, Ph.D., has three decades of experience in the biopharma industry. He is currently Chief Business Officer at Nasdaq-listed immunotherapeutics company Immatics, where he is responsible for corporate business development and strategic alliances. Throughout his career, Rainer delivered numerous strategic partnerships and license deals and held positions in research, business and corporate functions at companies such as Amgen, MorphoSys, Jerini, Shire and Signature Diagnostics.
 

About iOmx Therapeutics

iOmx Therapeutics (www.iomx.com) is a biopharmaceutical company focused on developing first-in-class cancer immuno-therapeutics addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company’s lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Biopharma. iOmx is based in Martinsried/Munich, Germany.

Contact

MC Services AG
Katja Arnold, Julia von Hummel, Shaun Brown
T: +49(0)89 2102280
iomx@mc-services.eu

 


20.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting